Novo Nordisk A/s

Innate Pharma S.a.s.

Novo Nordisk-a/s Novo Alle

University of Genoa

Innate Pharma

Anders Svensson

Peter Andreas Nicolai Reumert Wagtmann

Stefan Zahn

Søren Berg Padkær

Alessandro Moretta

Pascale Andre

Kristian Kjaergaard

Mariella Della Chiesa

Ivan Svendsen

Kristian Kjærgaard

Pieter Spee

Laurent Gauthier

Francois Romagne

Inger Lund Pedersen

Birgitte Urso

Matthias Thorolfsson

Michael Wilken

Lars Christian Petersen

Ida Hilden

Jes Thorn Clausen

Petrus Johannes Louis Spee

Henrik Oestergaard

Jianhe Chen

Prafull S Gandhi

Laust Bruun Johnsen

Soren Berg Padkjaer

Helle Heibroch Petersen

Rong Zhou

Per J Greisen

Brit Binow Soerensen

Karina Thorn

Mikkel Nors Harndahl

Bjarne Gram Hansen

Haisun Zhu

Morten Groenbech Rasch

Zhiru Yang

Francois Romagné

Pieter Johannes Louis Spee

Matthias Thórólfsson

Eva Johansson

Milchael Wilken

Petrus Johannes Loius Spee

Laurant Gauthier

Soren Berg Padkaer

Birgitte UrsØ

Søren Berg Padkaer

The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

Procoagulant antibodies

The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Antibodies against human NKG2D and uses thereof

The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.

KIR-binding agents and methods of use thereof

The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.

Antibodies that are capable of specifically binding tissue factor pathway inhibitor

The present invention provides isolated anti-human NKG2D monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient. Preferred antibodies include human monoclonal antibodies MS and 21 F2. As described herein, other antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules, can be designed or derived from such antibodies.

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

Nucleic acids encoding human anti-kir antibodies

Growing community of inventors

Malmö, Sweden

Anders Svensson